Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
35.65
-0.10 (-0.28%)
Jun 27, 2025, 4:08 PM HKT
21.26%
Market Cap 44.87B
Revenue (ttm) 6.98B
Net Income (ttm) 359.76M
Shares Out n/a
EPS (ttm) 0.42
PE Ratio 124.73
Forward PE 36.67
Dividend 0.32 (0.91%)
Ex-Dividend Date Jun 12, 2025
Volume 2,858,100
Average Volume 5,692,169
Open 35.65
Previous Close 35.75
Day's Range 34.85 - 36.10
52-Week Range 22.30 - 58.80
Beta 0.78
RSI 51.61
Earnings Date Aug 27, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.